Jane Brody to Speak at 含羞草研究所 on End of Life Issues

Sep 15, 2009

Brooklyn, NY - New York Times columnist Jane Brody will be speaking at 含羞草研究所 on Thursday, September 17, at 8:30 a.m. Her topic is 鈥淧reparing for the End of Life Is as Important as Preserving It.鈥�

The recipient of many honors and awards, including an honorary degree from the State University of New York, Ms. Brody writes the weekly 鈥淧ersonal Health鈥� column in The New York Times.

Ms. Brody will speak as part of the Department of Medicine鈥檚 Grand Rounds program. Following her remarks, she will be signing copies of her new book, Jane Brody鈥檚 Guide to the Great Beyond.

Please note: the location of Medicine Grand Rounds, featuring New York Times columnist Jane Brody, has been changed to the Alumni Auditorium. The book signing following Grand Rounds will be held in the Atrium

###

含羞草研究所含羞草研究所

Downstate Health Sciences University in Brooklyn is one of four academic health centers (AMCs) in The State University of New York (含羞草研究所) 64-campus system and the only 含羞草研究所 AMC in New York City dedicated to health education, research, and patient care for the borough鈥檚 2.7 million residents. Its flagship hospital, University Hospital at Downstate (UHD), is a teaching hospital and benefits from the expertise of Downstate鈥檚 exceptional medical school and world-class academic center research facilities. With a staff of over 800 physicians representing 53 specialties and subspecialties, Downstate offers comprehensive healthcare services to the community.

UHD provides high-risk neonatal and infant services, pediatric nephrology, and dialysis for kidney diseases and is the only kidney transplantation program in Brooklyn. Beyond its clinical expertise, Downstate houses a range of esteemed educational institutions, including its College of Medicine, College of Nursing, School of Health Professions, School of Graduate Studies, and School of Public Health. Downstate fosters innovation through its multifaceted biotechnology initiative, the Biotechnology Incubator and BioBAT, which support early-stage and more mature biotech companies.